American Heart Journal
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Effects of complete revascularization according to age in patients with ST-segment elevation myocardial infarction and multivessel disease (COMPLETE-AGE)
2024
-
Impact of a simple regimen of low molecular weight heparin (reviparin) in preventing mortality, reinfarction, and strokes in over 15,500 patients with ST-elevation acute myocardial infarction: The CREATE trial
2005
-
New anticoagulants
2001
-
Low-molecular-weight heparin for the treatment of venous thromboembolism
1998
-
Successors to heparin: New antithrombotic agents
1997
-
Pregnancy care experiences for adults with congenital heart disease in the United States..
280:30-41.
2025
-
Exploration of the regional effects of colchicine in the LoDoCo2 trial..
278:186-194.
2024
-
Outcome reporting in cardio-obstetrics studies: A systematic review..
278:223-234.
2024
-
Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design..
277:145-158.
2024
-
Design and rationale of the CLEAR SYNERGY (OASIS 9) trial: A 2x2 factorial randomized controlled trial of colchicine versus placebo and spironolactone vs placebo in patients with myocardial infarction.
275:173-182.
2024
-
The relative merits of using a high-sensitivity cardiac Troponin T assay compared to a nonhigh-sensitivity troponin T assay after noncardiac surgery.
275:45-52.
2024
-
A randomized clinical trial of catheter ablation and antiarrhythmic drug therapy for suppression of ventricular tachycardia in ischemic cardiomyopathy: The VANISH2 trial.
274:1-10.
2024
-
Computerized clinical decision support to improve stroke prevention therapy in primary care management of atrial fibrillation: a cluster randomized trial.
273:102-110.
2024
-
Identifying the highest risk vascular patients: Insights from the XATOA registry.
269:191-200.
2024
-
The prognostic significance of single-lead ST-segment resolution in ST-segment elevation myocardial infarction patients treated with primary PCI – A substudy of the randomized TOTAL trial.
269:149-157.
2024
-
Efficacy and safety of a bolus of half-dose r-SAK prior to primary PCI in ST-elevation myocardial infarction: Rationale and design of the OPTIMA-6 trial.
265:31-39.
2023
-
Inotrope versus placebo therapy in cardiogenic shock: Rationale and study design of the CAPITAL DOREMI2 trial.
262:83-89.
2023
-
Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC‐AF risk scores.
261:55-63.
2023
-
Rationale and design of the colchicine for the prevention of perioperative atrial fibrillation in patients undergoing major noncardiac thoracic surgery (COP-AF) trial.
259:87-96.
2023
-
Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: The COMPASS trial.
258:60-68.
2023
-
Characterization of arrhythmia substrate to ablate persistent atrial fibrillation (COAST-AF): Randomized controlled trial design and rationale.
254:133-140.
2022
-
Comparison of anticoagulation with left atrial appendage closure after atrial fibrillation ablation: Rationale and design of the OPTION randomized trial.
251:35-42.
2022
-
Lipid-lowering treatment intensity, persistence, adherence and goal attainment in patients with coronary heart disease.
251:78-90.
2022
-
OCEAN trial update.
248:169-169.
2022
-
Stopping renin-angiotensin system inhibitors after hyperkalemia and risk of adverse outcomes.
243:177-186.
2022
-
A randomized ablation-based atrial fibrillation rhythm control versus rate control trial in patients with heart failure and high burden atrial fibrillation: The RAFT-AF trial rationale and design.
234:90-100.
2021
-
Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale.
233:48-58.
2021
-
Association between levosimendan, postoperative AKI, and mortality in cardiac surgery: Insights from the LEVO-CTS trial.
231:18-24.
2021
-
High-Sensitivity Cardiac Troponin—Optimizing the Diagnosis of Acute Myocardial Infarction/Injury in Women (CODE-MI): Rationale and design for a multicenter, stepped-wedge, cluster-randomized trial.
229:18-28.
2020
-
A multinational registry to study the characteristics and outcomes of heart failure patients: The global congestive heart failure (G-CHF) registry.
227:56-63.
2020
-
The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation.
225:69-77.
2020
-
Integrated Management Program Advancing Community Treatment of Atrial Fibrillation (IMPACT-AF): A cluster randomized trial of a computerized clinical decision support tool.
224:35-46.
2020
-
Aldosterone-to-renin ratio and blood pressure in young adults from the general population.
222:199-207.
2020
-
Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both.
222:166-173.
2020
-
Clinical outcomes for chest pain patients discharged home from emergency departments using high-sensitivity versus conventional cardiac troponin assays.
221:84-94.
2020
-
Corrigendum to “Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): Rationale and design” [212 (2019) 36–44].
221:180-180.
2020
-
Association of plasma-soluble ST2 and galectin-3 with cardiovascular events and mortality following cardiac surgery.
220:253-263.
2020
-
Variations in stepped-wedge cluster randomized trial design: Insights from the Patient-Centered Care Transitions in Heart Failure trial.
220:116-126.
2020
-
Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease.
218:100-109.
2019
-
Opportunities for enhancing the care of older patients with ST-elevation myocardial infarction presenting for primary percutaneous coronary intervention: Rationale and design of the SAFE-STEMI for Seniors trial.
218:84-91.
2019
-
The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics.
218:46-56.
2019
-
Cardiovascular risk factor reduction by community health workers in rural India: A cluster randomized trial.
216:9-19.
2019
-
Design and rationale of the COMPLETE trial: A randomized, comparative effectiveness study of complete versus culprit-only percutaneous coronary intervention to treat multivessel coronary artery disease in patients presenting with ST-segment elevation myocardial infarction.
215:157-166.
2019
-
Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF.
213:35-46.
2019
-
Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): Rationale and design.
212:36-44.
2019
-
Stroke prevention in atrial fibrillation: Closing the gap.
210:29-38.
2019
-
Rationale and design of the randomized prospective ATLAS study: Avoid Transvenous Leads in Appropriate Subjects.
207:1-9.
2019
-
The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct.
206:72-79.
2018
-
Rationale and design of a cluster randomized trial of a multifaceted intervention in people with hypertension: The Heart Outcomes Prevention and Evaluation 4 (HOPE-4) Study.
203:57-66.
2018
-
Optimizing primary care management of atrial fibrillation: The rationale and methods of the Integrated Management Program Advancing Community Treatment of Atrial Fibrillation (IMPACT-AF) study.
201:149-157.
2018
-
Stroke type and severity in patients with subclinical atrial fibrillation: An analysis from the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial (ASSERT).
201:160-163.
2018
-
A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial.
199:51-58.
2018
-
Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants.
199:170-175.
2018
-
Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants?.
199:59-67.
2018
-
Knowledge to action: Rationale and design of the Patient-Centered Care Transitions in Heart Failure (PACT-HF) stepped wedge cluster randomized trial.
199:75-82.
2018
-
Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD).
199:83-91.
2018
-
Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time—A RE-LY trial analysis.
198:169-177.
2018
-
The Optimal Anti-Coagulation for Enhanced-Risk Patients Post–Catheter Ablation for Atrial Fibrillation (OCEAN) trial.
197:124-132.
2018
-
Mineralocorticoid receptor antagonists in patients with acute myocardial infarction — A systematic review and meta-analysis of randomized trials.
195:60-69.
2018
-
Predictors of perioperative major bleeding in patients who interrupt warfarin for an elective surgery or procedure: Analysis of the BRIDGE trial.
195:108-114.
2018
-
International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries.
194:132-140.
2017
-
Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI.
192:105-112.
2017
-
Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
190:94-103.
2017
-
Interventions Supporting Long-term Adherence aNd Decreasing cardiovascular events (ISLAND): Pragmatic randomized trial protocol.
190:64-75.
2017
-
Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial.
189:137-145.
2017
-
The epidemic of cardiovascular disease in South Asians: Time for action.
185:150-153.
2017
-
Atorvastatin for high-risk statin-naïve patients undergoing noncardiac surgery: The Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose (LOAD) randomized trial.
184:88-96.
2017
-
Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study.
182:125-134.
2016
-
Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sTudy (COAPT).
181:26-34.
2016
-
Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: Insights from the Canadian observational AntiPlatelet sTudy.
180:82-89.
2016
-
Utility of the LACE index at the bedside in predicting 30-day readmission or death in patients hospitalized with heart failure.
179:51-58.
2016
-
Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study.
178:145-150.
2016
-
NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank.
177:74-86.
2016
-
Rationale and design of a home-based trial using wearable sensors to detect asymptomatic atrial fibrillation in a targeted population: The mHealth Screening To Prevent Strokes (mSToPS) trial.
175:77-85.
2016
-
Optimal medical therapy with or without percutaneous coronary intervention in women with stable coronary disease: A pre-specified subset analysis of the Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation (COURAGE) trial.
173:108-117.
2016
-
Strategy of continued vs interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: The BRUISE CONTROL-2 trial.
173:102-107.
2016
-
Corrigendum to “Heart failure in low- and middle-income countries: Background, rationale, and design of the INTERnational Congestive Heart Failure Study (INTER-CHF)” (Am Heart J. 2015;170[4]:627-634).
172:201-201.
2016
-
Culprit vessel versus immediate complete revascularization in patients with ST-segment myocardial infarction—a systematic review.
170:1133-1139.
2015
-
Cluster randomized controlled trial of Delayed Educational Reminders for Long-term Medication Adherence in ST-Elevation Myocardial Infarction (DERLA-STEMI).
170:903-913.
2015
-
Radial versus femoral access for elderly patients with acute coronary syndrome undergoing coronary angiography and intervention: insights from the RIVAL trial.
170:880-886.
2015
-
Heart failure in low- and middle-income countries: Background, rationale, and design of the INTERnational Congestive Heart Failure Study (INTER-CHF).
170:627-634.e1.
2015
-
Impact of access site choice on outcomes of patients with cardiogenic shock undergoing percutaneous coronary intervention: A systematic review and meta-analysis.
170:353-361.e6.
2015
-
Effects of the dual peroxisome proliferator–activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes.
170:117-122.
2015
-
Effects of withdrawing vs continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: Results from the Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker and Contrast Induced Nephropathy in Patients Receiving Cardiac Catheterization (CAPTAIN) trial.
170:110-116.
2015
-
Socioeconomic status and risk of hemorrhage during warfarin therapy for atrial fibrillation: A population-based study.
170:133-140.e3.
2015
-
The choice of arterial access for percutaneous coronary intervention and its impact on outcome: An expert opinion perspective.
170:13-22.
2015
-
Novel oral anticoagulants and reversal agents: Considerations for clinical development.
169:751-757.
2015
-
A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
169:597-604.e5.
2015
-
Impact of weight reduction on pericardial adipose tissue and cardiac structure in patients with atrial fibrillation.
169:655-662.e2.
2015
-
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo.
169:631-638.e7.
2015
-
A novel coronary angiography index (DILEMMA score) for prediction of functionally significant coronary artery stenoses assessed by fractional flow reserve: A novel coronary angiography index.
169:564-571.e4.
2015
-
Transition from apixaban to warfarin—addressing excess stroke, systemic embolism, and major bleeding.
169:1-3.
2015
-
Cognitive status in patients hospitalized with acute decompensated heart failure.
168:917-923.
2014
-
Rationale and design of a randomized controlled trial evaluating community health worker–based interventions for the secondary prevention of acute coronary syndromes in India (SPREAD).
168:690-697.
2014
-
Sevoflurane in acute myocardial infarction: A pilot randomized study.
168:776-783.
2014
-
Transesophageal echocardiography in patients with cryptogenic ischemic stroke: A systematic review.
168:706-712.e14.
2014
-
Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012.
168:239-247.e1.
2014
-
Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial.
168:23-29.e2.
2014
-
Rationale and design of the PeriOperative ISchemic Evaluation-2 (POISE-2) trial: An international 2 × 2 factorial randomized controlled trial of acetyl-salicylic acid vs placebo and clonidine vs placebo in patients undergoing noncardiac surgery.
167:804-809.e4.
2014
-
Rationale and design of the Steroids in Cardiac Surgery trial.
167:660-665.
2014
-
Resuscitation Outcomes Consortium–Amiodarone, Lidocaine or Placebo Study (ROC-ALPS): Rationale and methodology behind an out-of-hospital cardiac arrest antiarrhythmic drug trial.
167:653-659.e4.
2014
-
Design and rationale of the TOTAL trial: A randomized trial of routine aspiration ThrOmbecTomy with percutaneous coronary intervention (PCI) versus PCI ALone in patients with ST-elevation myocardial infarction undergoing primary PCI.
167:315-321.e1.
2014
-
Complete vs culprit-only revascularization for patients with multivessel disease undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: A systematic review and meta-analysis.
167:1-14.e2.
2014
-
Prospective Urban Rural Epidemiology (PURE) study: Baseline characteristics of the household sample and comparative analyses with national data in 17 countries.
166:636-646.e4.
2013
-
Embedding a randomized clinical trial into an ongoing registry infrastructure: Unique opportunities for efficiency in design of the Study of Access site For Enhancement of Percutaneous Coronary Intervention for Women (SAFE-PCI for Women).
166:421-428.e1.
2013
-
Prognostic importance of coronary anatomy and left ventricular ejection fraction despite optimal therapy: Assessment of residual risk in the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation Trial.
166:481-487.
2013
-
Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease.
166:306-314.e7.
2013
-
Rationale and design of the Primary pREvention strategies at the community level to Promote Adherence of treatments to pREvent cardiovascular diseases trial number (CTRI/2012/09/002981).
166:4-12.e1.
2013
-
Clinical outcomes and cost implications of routine early PCI after fibrinolysis: One-year follow-up of the Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI) study.
165:630-637.e2.
2013
-
Rationale and design of the ATTRACT Study: A multicenter randomized trial to evaluate pharmacomechanical catheter-directed thrombolysis for the prevention of postthrombotic syndrome in patients with proximal deep vein thrombosis.
165:523-530.e3.
2013
-
Rationale and design of the Investigation of the Management of Pericarditis (IMPI) trial: A 2 × 2 factorial randomized double-blind multicenter trial of adjunctive prednisolone and Mycobacterium w immunotherapy in tuberculous pericarditis.
165:109-115.e3.
2013
-
Design and rationale of the Treatment of Acute Coronary Syndromes with Otamixaban trial: A double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non–ST-segment elevation acute coronary syndromes with a planned early invasive strategy.
164:817-824.e13.
2012
-
Efficacy of early invasive management post-fibrinolysis in men versus women with ST-elevation myocardial infarction: A subgroup analysis from Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI).
164:343-350.
2012
-
Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention.
164:243-250.
2012
-
Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: The Transthyretin Amyloidosis Cardiac Study (TRACS).
164:222-228.e1.
2012
-
The rationale and design of the Shockless IMPLant Evaluation (SIMPLE) trial: A randomized, controlled trial of defibrillation testing at the time of defibrillator implantation.
164:146-152.
2012
-
A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: The Randomized, phase II study to Evaluate the sAfety and pharmacokinetics of oraL dabIGatran etexilate in patients after heart valve replacemeNt (RE-ALIGN).
163:931-937.e1.
2012
-
Authors' reply to “Could radial instead of femoral access for coronary angiography change renal outcome? Nephrologists call for help”.
163:e21-e21.
2012
-
Comparison of transradial and femoral approaches for percutaneous coronary interventions: A systematic review and hierarchical Bayesian meta-analysis.
163:632-648.
2012
-
Preventing cardiovascular disease in primary care: Role of a national risk factor management program.
163:714-719.
2012
-
Rationale and design of a Global Rheumatic Heart Disease Registry: The REMEDY study.
163:535-540.e1.
2012
-
International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD).
163:13-19.e1.
2012
-
Rationale and design of The Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization Study: A large international randomized trial in cardiac surgery.
163:1-6.
2012
-
Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
162:900-906.
2011
-
Management of acute coronary syndromes in developing countries: ACute Coronary Events—a multinational Survey of current management Strategies.
162:852-859.e22.
2011
-
Design and rationale of the RadIal Vs. femorAL access for coronary intervention (RIVAL) trial: A randomized comparison of radial versus femoral access for coronary angiography or intervention in patients with acute coronary syndromes (vol 161, pg 254 2011).
161:1221-1221.
2011
-
Effect of rosuvastatin on C-reactive protein and progression of aortic stenosis.
161:1133-1139.
2011
-
Clinical outcomes after percutaneous revascularization versus medical management in patients with significant renal artery stenosis: A meta-analysis of randomized controlled trials.
161:622-630.e1.
2011
-
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol.
161:471-477.e2.
2011
-
Design and rationale of the RadIal Vs. femorAL access for coronary intervention (RIVAL) trial: A randomized comparison of radial versus femoral access for coronary angiography or intervention in patients with acute coronary syndromes.
161:254-260.e4.
2011
-
Efficacy and safety of fondaparinux in patients with ST-segment elevation myocardial infarction across the age spectrum. Results from the Organization for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) trial.
160:1049-1055.
2010
-
Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): A randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non–ST-segment elevation acute coronary syndromes initially treated with fondaparinux.
160:1029-1034.e1.
2010
-
Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study.
160:1178-1184.
2010
-
The Fat-Mass and Obesity-Associated (FTO) gene, physical activity, and risk of incident cardiovascular events in white women.
160:1163-1169.
2010
-
Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: Insights from the Global Registry of Acute Coronary Events.
160:855-861.
2010
-
Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.
160:785-794.e10.
2010
-
Temporal trend of in-hospital major bleeding among patients with non ST-elevation acute coronary syndromes.
160:420-427.
2010
-
Incidence and clinical relevance of anti–platelet factor 4/heparin antibodies before cardiac surgery.
160:362-369.
2010
-
Clinical outcomes trials and the cardiovascular effects of thiazolidinediones: Implications for the evaluation of antidiabetic drugs.
160:1-2.
2010
-
Duration of red cell storage before transfusion and in-hospital mortality.
159:737-743.e1.
2010
-
Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment.
159:348-353.e1.
2010
-
Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: A proposal from the Academic Bleeding Consensus (ABC) Multidisciplinary Working Group.
158:881-886.e1.
2009
-
Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in non–ST-elevation acute coronary syndrome patients: The Canadian Global Registry of Acute Coronary Events (GRACE) experience.
158:917-924.
2009
-
N-terminal pro–brain natriuretic peptide and exercise capacity in chronic heart failure: Data from the Heart Failure and a Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study.
158:S37-S44.
2009
-
Safety of symptom-limited cardiopulmonary exercise testing in patients with chronic heart failure due to severe left ventricular systolic dysfunction.
158:S72-S77.
2009
-
The Family Atherosclerosis Monitoring In earLY life (FAMILY) study.
158:533-539.
2009
-
The Prospective Urban Rural Epidemiology (PURE) study: Examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countries.
158:1-7.e1.
2009
-
Fondaparinux versus Enoxaparin in non–ST-elevation acute coronary syndromes: Short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial.
157:845-852.
2009
-
Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran.
157:805-810.e2.
2009
-
Candidate genetic variants in the fibrinogen, methylenetetrahydrofolate reductase, and intercellular adhesion molecule-1 genes and plasma levels of fibrinogen, homocysteine, and intercellular adhesion molecule-1 among various race/ethnic groups: Data from the Women's Genome Health Study.
157:777-783.e1.
2009
-
Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarction.
157:763-770.
2009
-
Temporal trends and patterns of early clopidogrel use across the spectrum of acute coronary syndromes.
157:642-650.e1.
2009
-
Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: Outcomes and treatment effect across different levels of risk.
157:502-508.
2009
-
Nitrous oxide and perioperative cardiac morbidity (ENIGMA-II) Trial: Rationale and design.
157:488-494.e1.
2009
-
Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: A systematic review and meta-analysis of randomized trials.
157:132-140.
2009
-
Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non–ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: Results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial.
157:60.e1-60.e9.
2009
-
Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): Study design and baseline characteristics.
156:1074-1079.
2008
-
Design and rationale of CURRENT-OASIS 7: A randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non–ST-elevation acute coronary syndromes managed with an early invasive strategy.
156:1080-1088.e1.
2008
-
Cardiovascular sequelae of preeclampsia/eclampsia: A systematic review and meta-analyses.
156:918-930.
2008
-
Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease.
156:719-727.
2008
-
An early invasive strategy versus ischemia-guided management after fibrinolytic therapy for ST-segment elevation myocardial infarction: A meta-analysis of contemporary randomized controlled trials.
156:564-572.e2.
2008
-
Angiotensin inhibition in renovascular disease: A population-based cohort study.
156:549-555.
2008
-
Thirty-year trends (1975-2005) in the magnitude and hospital death rates associated with complete heart block in patients with acute myocardial infarction: A population-based perspective.
156:227-233.
2008
-
Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: The BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT).
156:37-43.
2008
-
Safety and effectiveness of drug-eluting stents among diabetic patients: A propensity analysis.
156:125-134.
2008
-
Computed tomographic coronary angiographic assessment of high-risk coronary anatomy in patients with suspected coronary artery disease and intermediate pretest probability.
155:918-923.
2008
-
Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use.
155:910-917.
2008
-
Quantitative troponin elevation does not provide incremental prognostic value beyond comprehensive risk stratification in patients with non–ST-segment elevation acute coronary syndromes.
155:718-724.
2008
-
Life expectancy after an index hospitalization for patients with heart failure: A population-based study.
155:324-331.
2008
-
Monitoring the ACTIVE-W trial: Some issues in monitoring a noninferiority trial.
155:33-41.
2008
-
Rationale and design of the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI).
155:19-25.
2008
-
Rationale and design of the trial of routine angioplasty and stenting after fibrinolysis to enhance reperfusion in acute myocardial infarction (TRANSFER-AMI).
155:19-25.
2008
-
Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention).
155:26.e1-26.e13.
2008
-
Letter to the Editor.
154:e29-e29.
2007
-
Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy.
154:899-907.
2007
-
Infarct size, ejection fraction, and mortality in diabetic patients with acute myocardial infarction treated with thrombolytic therapy.
154:743-750.
2007
-
Coronary artery disease - Impact of ramipril on the incidence of atrial fibrillation: Results of the Heart Outcomes Prevention Evaluation study.
154:448-453.
2007
-
Impact of ramipril on the incidence of atrial fibrillation: Results of the Heart Outcomes Prevention Evaluation study.
154:448-453.
2007
-
Inpatient smoking-cessation counseling and all-cause mortality in patients with acute myocardial infarction.
154:213-220.
2007
-
Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: Substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND).
154:94-101.
2007
-
Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation.
153:1006-1012.
2007
-
Preventing tomorrow's sudden cardiac death today.
153:941-950.
2007
-
Preventing tomorrow's sudden cardiac death today.
153:951-959.
2007
-
Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis.
153:925-931.
2007
-
Response to the Letter to the Editor by Dr Wijeysundera.
153:e19-e19.
2007
-
Response to “Letter to the Editor”.
153:e27-e27.
2007
-
A community-wide perspective into changing trends in the utilization of diagnostic and interventional procedures in patients hospitalized with acute myocardial infarction.
153:594-605.
2007
-
Relation between cardiac troponin I and mortality in acute decompensated heart failure.
153:462-470.
2007
-
Extent and distribution of coronary artery disease: A comparative study of invasive versus noninvasive angiography with computed angiography.
153:378-384.
2007
-
Grade 3 ischemia on the admission electrocardiogram predicts failure of ST resolution and of adequate flow restoration after primary percutaneous coronary intervention for acute myocardial infarction.
153:410-417.
2007
-
Treatment practices and outcomes of patients with established peripheral arterial disease hospitalized with acute myocardial infarction in a community setting.
153:140-146.
2007
-
Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial.
152:887.e9-887.e14.
2006
-
The effects of perioperative β-blockade: Results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial.
152:983-990.
2006
-
ASymptomatic atrial fibrillation and Stroke Evaluation in pacemaker patients and the atrial fibrillation Reduction atrial pacing Trial (ASSERT).
152:442-447.
2006
-
Rationale, design, and organization of the PeriOperative ISchemic Evaluation (POISE) Trial: A randomized controlled trial of metoprolol versus placebo in patients undergoing noncardiac surgery.
152:223-230.
2006
-
Borderline left ventricles in prenatally diagnosed atrioventricular septal defect or double outlet right ventricle: Echocardiographic predictors of biventricular repair.
152:163.e1-163.e7.
2006
-
Persistence and adherence to cholesterol lowering agents: Evidence from Régie de l'Assurance Maladie du Québec data.
152:164-169.
2006
-
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
152:86-92.
2006
-
The impact of the ESC/ACC redefinition of myocardial infarction and new sensitive troponin assays on the frequency of acute myocardial infarction.
152:118-125.
2006
-
Benefits of left atrial appendage occlusion.
151:e3-e3.
2006
-
Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial.
151:1173-1179.
2006
-
Economics methods in the Clinical Outcomes Utilizing percutaneous coronary Revascularization and Aggressive Guideline-driven drug Evaluation (COURAGE) trial.
151:1180-1185.
2006
-
Effect of exercise training on myocardial blood flow in patients with stable coronary artery disease.
151:1324.e11-1324.e18.
2006
-
Excess body weight, clinical profile, management practices, and hospital prognosis in men and women after acute myocardial infarction.
151:1297-1304.
2006
-
Rationale and design of ACTIVE: The atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events.
151:1187-1193.
2006
-
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program..
151:985-991.
2006
-
Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)–Added trial.
151:985-991.
2006
-
Homocysteine-lowering trials for prevention of cardiovascular events: A review of the design and power of the large randomized trials.
151:282-287.
2006
-
A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions.
151:175.e1-175.e6.
2006
-
Changing trends in the long-term prognosis of patients with acute myocardial infarction: A population-based perspective.
151:199-205.
2006
-
Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation.
151:219-227.
2006
-
The effects of oral anticoagulants in patients with peripheral arterial disease: Rationale, design, and baseline characteristics of the Warfarin and Antiplatelet Vascular Evaluation (WAVE) trial, including a meta-analysis of trials.
151:1-9.
2006
-
Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: Further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
150:1177-1184.
2005
-
Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)–5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non–ST-segment elevation acute coronary syndromes.
150:1107.e1-1107.e10.
2005
-
Pilot study to determine the impact of a multidisciplinary educational intervention in patients hospitalized with heart failure.
150:982.e1-982.e9.
2005
-
Racial differences in outcome and treatment effect in congestive heart failure.
150:968-976.
2005
-
Decade-long changes in the use of combination evidence–based medical therapy at discharge for patients surviving acute myocardial infarction.
150:838-844.
2005
-
Radial versus femoral access for emergent percutaneous coronary intervention with adjunct glycoprotein IIb/IIIa inhibition in acute myocardial infarction—the RADIAL-AMI pilot randomized trial.
150:543-549.
2005
-
Left Atrial Appendage Occlusion Study (LAAOS): Results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke.
150:288-293.
2005
-
Methodological design for economic evaluation in Public Access Defibrillation (PAD) trial.
150:202-208.
2005
-
A review of the oral direct thrombin inhibitor ximelagatran.
150:19-26.
2005
-
Management of risk in peripheral artery disease: Recent therapeutic advances.
150:35-40.
2005
-
The clinical challenge of bridging anticoagulation with low-molecular-weight heparin in patients with mechanical prosthetic heart valves: An evidence-based comparative review focusing on anticoagulation options in pregnant and nonpregnant patients.
150:27-34.
2005
-
Heart rate variability biofeedback as a behavioral neurocardiac intervention to enhance vagal heart rate control.
149:1137.e1-1137.e7.
2005
-
Angiotensin-converting enzyme inhibitors as a new therapy for atrial fibrillation? Controversy.
149:e19-e19.
2005
-
Conducting economic evaluations alongside multinational clinical trials: Toward a research consensus.
149:434-443.
2005
-
Letter to the editor.
149:e21-e21.
2005
-
Impact of age on management and outcome of acute coronary syndrome: Observations from the global registry of acute coronary events (GRACE).
149:67-73.
2005
-
Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease.
149:54-60.
2005
-
Thromboepidemiology: Identifying patients with heritable risk for thrombin-mediated thromboembolic events.
149:S9-S18.
2005
-
Challenges in the conduct of large simple trials of important generic questions in resource-poor settings: The CREATE and ECLA trial program evaluating GIK (glucose, insulin and potassium) and low-molecular-weight heparin in acute myocardial infarction.
148:1068-1078.
2004
-
Transforming the scientific, health care, and sociopolitical culture of an entire country through clinical research: The story of GISSI.
148:193-195.
2004
-
Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
148:52-61.
2004
-
Tackling the challenge of cardiovascular disease burden in developing countries.
148:1-4.
2004
-
Diminishing proportional risk of sudden death with advancing age: implications for prevention of sudden death.
147:837-840.
2004
-
When guidelines collide.
147:395-397.
2004
-
Effectiveness of primary percutaneous coronary intervention compared with that of thrombolytic therapy in elderly patients with acute myocardial infarction11Guest Editor for this manuscript was Peter B. Berger, MD, Mayo Clinic, Rochester, Minn..
147:253-259.
2004
-
Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine.
146:291-297.
2003
-
Risk factors for myocardial infarction in Brazil.
146:331-338.
2003
-
Prognostic importance of the oxidized product of catecholamines, adrenolutin, in patients with severe heart failure.
145:926-932.
2003
-
Prognostic importance of the oxidized product of catecholamines, adrenolutin, in patients with severe heart failure.
145:926-932.
2003
-
Two-decade-long trends (1975-1997) in the incidence, hospitalization, and long-term death rates associated with complete heart block complicating acute myocardial infarction: A community-wide perspective.
145:500-507.
2003
-
Double-blind, placebo-controlled, randomized trial of prophylactic metoprolol for reduction of hospital length of stay after heart surgery: The β-Blocker Length Of Stay (BLOS) study.
145:226-232.
2003
-
Left Atrial Appendage Occlusion Study (LAAOS): A randomized clinical trial of left atrial appendage occlusion during routine coronary artery bypass graft surgery for long-term stroke prevention.
145:174-178.
2003
-
Does chronic Chlamydia pneumoniae infection increase the risk of myocardial injury? Insights from patients with non-ST-elevation acute coronary syndromes.
144:987-994.
2002
-
The relevance of subgroup-specific treatment effects: The Studies Of Left Ventricular Dysfunction (SOLVD) revisited.
144:941-947.
2002
-
Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: The Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial.
144:597-607.
2002
-
Changes over time in the use of aspirin in patients hospitalized with acute myocardial infarction (1975 to 1997): A population-based perspective.
144:259-268.
2002
-
Quality of life in the Canadian Implantable Defibrillator Study (CIDS).
144:282-289.
2002
-
Effects of exercise training in patients with heart failure: The Exercise Rehabilitation Trial (EXERT).
144:23-30.
2002
-
Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension.
143:4A-10A.
2002
-
Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes.
143:753-759.
2002
-
Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa receptor-directed platelet inhibition.
143:725-732.
2002
-
Choice of clinical outcomes in randomized trials of heart failure therapies: Disease-specific or overall outcomes?.
143:22-28.
2002
-
Six-month outcomes of percutaneous transluminal coronary angioplasty in hypertensive patients: Results from the ROSETTA registry.
143:124-129.
2002
-
Coronary stenting in diabetic patients: Results from the ROSETTA registry.
142:960-964.
2001
-
Decade-long trends (1986 to 1997) in the medical treatment of patients with acute myocardial infarction: A community-wide perspective.
142:594-603.
2001
-
Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction.
142:617-623.
2001
-
Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction.
142:617-623.
2001
-
Reliability, validity, and responsiveness of the six-minute walk test in patients with heart failure.
142:698-703.
2001
-
Cost-effectiveness of β-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada.
142:537-543.
2001
-
Primary percutaneous coronary interventions in patients with acute myocardial infarction and prior coronary artery bypass grafting.
142:452-459.
2001
-
Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa (αIIb/β3) receptor-directed platelet inhibition.
142:204-210.
2001
-
Conclusion.
142:S30-S30.
2001
-
Introduction.
142:S1-S2.
2001
-
New anticoagulants..
142:S3-S8.
2001
-
Pentasaccharide Org31540/SR90107A clinical trials update: Lessons for practice.
142:S9-S15.
2001
-
Predictors of improvement in left ventricular function after percutaneous revascularization of occluded coronary arteries: A report from the Total Occlusion Study of Canada (TOSCA).
142:301-308.
2001
-
Randomized comparison of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: Results of the VITAL study (Vasoflux International Trial for Acute Myocardial Infarction Lysis).
142:237-243.
2001
-
Pathobiologic features and prevention of thrombotic complications associated with prosthetic heart valves: Fundamental principles and the contribution of platelets and thrombin.
141:1025-1037.
2001
-
INTER-HEART: A global study of risk factors for acute myocardial infarction.
141:711-721.
2001
-
The Data and Safety Monitoring Committee: Some final thoughts.
141:548-549.
2001
-
The Defibrillator in Acute Myocardial Infarction Trial (DINAMIT): Study protocol.
140:735-739.
2000
-
Recommendations for national and local regulatory authorities concerning research in genetic markers of disease.
140:S3-S5.
2000
-
Collaborative Angiographic Patency Trial Of Recombinant Staphylokinase (CAPTORS).
139:820-823.
2000
-
Challenges in the conduct and interpretation of phase II (pilot) randomized trials.
139:S136-S142.
2000
-
Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors.
139:609-617.
2000
-
Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?.
139:423-429.
2000
-
Long-term nitrate use in chronic coronary artery disease: Need for a randomized controlled trial.
138:400-402.
1999
-
Economic issues in glycoprotein IIb/IIIa receptor therapy.
138:s24-s32.
1999
-
Insights into the contemporary epidemiology and outpatient management of congestive heart failure.
138:87-94.
1999
-
Recovery rates of regional sympathetic reinnervation and myocardial blood flow after acute myocardial infarction.
137:863-869.
1999
-
Use of bedside activated partial thromboplastin time monitor to adjust heparin dosing after thrombolysis for acute myocardial infarction: Results of GUSTO-I.
136:868-876.
1998
-
Use of bedside activated partial thromboplastin time monitor to adjust heparin dosing after thrombolysis for acute myocardial infarction: results of GUSTO-I. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries..
136:868-876.
1998
-
Low-molecular-weight heparin for the treatment of venous thromboembolism..
135:S336-S342.
1998
-
Pharmacology of the low-molecular-weight heparins.
135:S329-S335.
1998
-
Early assessment and in-hospital management of patients with acute myocardial infarction at increased risk for adverse outcomes: A nationwide perspective of current clinical practice.
135:786-796.
1998
-
Early assessment and in-hospital management of patients with acute myocardial infarction at increased risk for adverse outcomes: a nationwide perspective of current clinical practice. The National Registry of Myocardial Infarction (NRMI-2) Participants..
135:786-796.
1998
-
Heart failure between 1986 and 1994: Temporal trends in drug-prescribing practices, hospital readmissions, and survival at an academic medical center.
134:901-909.
1997
-
Successors to heparin: new antithrombotic agents..
134:S71-S77.
1997
-
Systolic function, readmission rates, and survival among consecutively hospitalized patients with congestive heart failure.
134:728-736.
1997
-
Acute and long-term effects of the angiotensin-converting enzyme inhibitor, enalapril, on adrenergic activity and sensitivity during exercise in patients with left ventricular systolic dysfunction.
134:37-43.
1997
-
Tolerability of enalapril initiation by patients with left ventricular dysfunction: Results of the medication challenge phase of the studies of left ventricular dysfunction.
128:358-364.
1994
-
The impact of left ventricular dysfunction on outcomes with the implantable defibrillator.
127:1159-1163.
1994
-
Antithrombotic therapy in deep vein thrombosis and pulmonary embolism.
123:1115-1122.
1992
-
Antithrombotic therapy in deep vein thrombosis and pulmonary embolism..
123:1115-1122.
1992
-
A critical review of the relationship between impaired fibrinolysis and myocardial infarction.
122:545-551.
1991
-
Atrial and ventricular arrhythmias in asymptomatic active elderly subjects: Correlation with left atrial size and left ventricular mass.
119:1069-1076.
1990
-
Oxygen uptake and heart rate during cross-country skiing and track walking after myocardial infarction.
117:495-497.
1989
-
An unusual artifactual cause of apparent atrial flutter.
117:202-204.
1989
-
Concentration response relationships of amiodarone and desethylamiodarone.
115:1208-1213.
1988
-
Effect of nafazatrom on platelet function and release: Relationship to symptomatic episodes in patients with peripheral vascular disease.
113:1133-1137.
1987
-
Reply.
106:1449-1450.
1983
-
Assessment of the accuracy of serial electrocardiograms in the diagnosis of myocardial infarction.
105:258-261.
1983
-
Ischemic pain relief in patients with acute myocardial infarction by intravenous atenolol.
103:459-467.
1982
-
Exercise rehabilitation of female patients with coronary heart disease.
100:755-757.
1980
-
Reply.
96:422-423.
1978
-
Hypertension control, compliance and science.
94:666-667.
1977
-
Cardiac actions of kaliuretics and antikaliuretics without digitalis.
92:124-125.
1976
-
Anticoagulants in pregnancy: A review of indications and complications.
83:301-305.
1972
-
Hemodynamic effects of two beta-adrenergic blocking drugs in anesthetized intact dogs.
72:38-49.
1966
-
Hypophysectomy and heart size.
71:570-571.
1966
-
Alcohol and the heart.
69:422-423.
1965
-
La mort d'amour.
69:287-287.
1965
-
Thromboaortitis.
68:572-574.
1964
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)